Horse owner experiences and observations with the use of SGLT2i for the management of equine metabolic syndrome and hyperinsulinaemia‐associated laminitis

Equine Veterinary Education, Год журнала: 2024, Номер unknown

Опубликована: Апрель 8, 2024

Summary Background Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) are being used increasingly in equine practice. While there is emerging clinical evidence of the safety and efficacy these drugs, currently no reports to document owner experiences with treatment. Objective The objective study was report observations following treatment SGLT2i horses. Study design A cross‐sectional online survey. Methods Horse owners were recruited via social media, forums their veterinarians participate an anonymous survey when treating horses SGLT2i. Results Three hundred forty‐two responses met inclusion criteria. Ertugliflozin most commonly prescribed (79.8%), common reasons for high insulin concentrations (84.2%) active laminitis (59.7%). 85.3% reported had improved quality life after commencing treatment, while 9.4% change 5.3% a worsening signs. Of who considered euthanasia prior ( n = 77), 80.5% horse's level pain be either mild or absent 30 days 94.8% improved. Most 220, 64.7%) they extremely satisfied somewhat 72, 21.2%) Treatment concerns included safety/side effects, medication cost, availability long‐term efficacy. 114 (33.3%) one more initial adverse effects upon induction onto medication, particularly excessive urination 70, 20.5%), drinking 38, 11.1%), weight loss 34, 9.9%) dullness 26, 7.6%). Main limitation Sampling bias through media veterinary practices reliance on subjective reports. Conclusion use associated excellent rates satisfaction owner‐reported horse; however, some observed.

Язык: Английский

---

Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium‐glucose cotransporter‐2 inhibitor and glucagon‐like peptide‐1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease

Diabetes Obesity and Metabolism, Год журнала: 2024, Номер 26(8), С. 3248 - 3260

Опубликована: Май 19, 2024

Abstract Aim To conduct a post hoc subgroup analysis of patients with type 2 diabetes (T2D) from the RECAP study, who were treated sodium‐glucose cotransporter‐2 (SGLT2) inhibitor and glucagon‐like peptide 1 receptor agonist (GLP‐1RA) combination therapy, focusing only on those had chronic kidney disease (CKD), to examine whether composite renal outcome differed between received SGLT2 treatment first GLP‐1RA first. Methods We included 438 CKD (GLP‐1RA‐first group, n = 223; inhibitor‐first 215) 643 T2D in study. The incidence outcome, defined as progression macroalbuminuria and/or ≥50% decrease estimated glomerular filtration rate (eGFR), was analysed using propensity score (PS)‐matched model. Furthermore, we calculated win ratio for these outcomes, which weighted following order: (1) both eGFR macroalbuminuria; (2) only; (3) only. Results Using PS‐matched model, 132 each group paired. outcomes did not differ two groups 10%; 17%; odds 1.80; 95% confidence interval [CI] 0.85 4.26; p 0.12). GLP‐1RA‐first versus 1.83 (95% CI 1.71 1.95; < 0.001). Conclusion Although groups, significant. These results suggest that, addition an baseline may lead more favourable outcomes.

Язык: Английский

---

The Impact of the Withdrawal of SGLT2 Inhibitors on Clinical Outcomes in Patients with Heart Failure

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(11), С. 3196 - 3196

Опубликована: Май 29, 2024

Background: The clinical impact of the withdrawal sodium-glucose cotransporter 2 inhibitors (SGLT2i) on all-cause readmission in patients with heart failure remains unknown. Methods: We enrolled a total 212 consecutive who were hospitalized for and received SGLT2i during their index hospitalization between February 2016 July 2022. Of these patients, 51 terminated or after hospitalization. evaluated prognostic primary outcome, which was defined as rate/times. Results: Over median 23.2 months, occurred 38 out (74.5%) withdrawn from 93 161 (57.8%) continuation (p = 0.099). incidence readmissions per year 0.97 [0-1.50] 0.50 [0-1.03] 0.030). There no significant difference medical costs (62,906 [502-187,246] versus 29,236 [7920-180,305] JPY month, p 0.866) both patient groups. Conclusions: Termination may be associated incremental benefit reducing costs.

Язык: Английский

---

Effect of Sodium-Glucose Cotransporter Type 2 Inhibitors on The Development and Course of Atrial Fibrillation

The Russian Archives of Internal Medicine, Год журнала: 2025, Номер 15(1), С. 17 - 23

Опубликована: Янв. 26, 2025

Atrial fibrillation is one of the most common heart rhythm disorders associated with an increased risk stroke, cardiovascular mortality and hospitalizations. The development arrhythmias influenced by a number factors, including arterial hypertension, chronic failure, coronary disease endocrine disorders. New guidelines from European Society Cardiology (2024) emphasize importance managing factors to improve treatment efficacy prognosis in patients atrial fibrillation. Sodium-glucose cotransporter type 2 inhibitors (gliflozins), originally used as hypoglycemic drugs, are now also widely reduce adverse events. However, use these drugs course remains open question. In order find answer this question, literature review was conducted, which showed that sodium-glucose can theoretically have antiarrhythmic effect realized through several mechanisms. Analysis scientific data suggests cases, reduces first-time fibrillation, has positive on arrhythmia its recurrence after ablation. At same time, it not clear end whether discussed issues class-effect or belonging gliflozin group different efficacy. mentioned necessitate further prospective studies confirm sodiumglucose inhibitors.

Язык: Английский

---

SGLT-2 inhibitors on cardiac autonomic function in individuals with and without type 2 diabetes mellitus

Journal of Diabetes and its Complications, Год журнала: 2025, Номер unknown, С. 109021 - 109021

Опубликована: Март 1, 2025

Язык: Английский

---